Moderna's Data From Personalized Cancer Vaccine Provides Relief To Investors, Analyst Says

  • Moderna Inc MRNA and Merck & Co Inc's MRK investigational personalized mRNA cancer vaccine + Keytruda demonstrated a statistically significant and clinically meaningful improvement in recurrence-free survival versus Keytruda.
  • SVB Leerink has raised the price target on Moderna from $101 to $102.
  • The analyst says it has fielded a steady stream of inbounds from investors nervous about elevated expectations for personalized cancer vaccine (PCV) data and expects shares to trade up on relief in response to this data. 
  • The analyst expects the applicability of PCV outside of this setting to drive controversy as investors debate how directly one can translate data in Melanoma to other indications.
  • Oppenheimer keeps Neutral rating on Moderna. The analyst says that China's sales could be a near-term tailwind, but competition and pricing pressure could put downward pressure on MRNA's mid/long-term margins.
  • The analyst also writes that any order from China of mRNA vaccines for the 2023/24 fall season might take a few more months to formalize. 
  • Price Action: MRNA shares are up 23.60% at $204.18 on the last check Tuesday
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!